Skip to main content
TipRanks
Go Ultimate75% OFF

Klaus Paulini Insider Profile

4 Followers

Klaus Paulini, President & Chief Executive Officer at COSCIENS Biopharma, holds 105.00K shares in COSCIENS Biopharma (Ticker: CSCIF). Most recently, Klaus Paulini Bought 50,000 shares of COSCIENS Biopharma on May 20, 2022 for an estimated value of $9.84K.

Klaus Paulini's Trading History

CSCIF
COSCIENS Biopharma
May 20, 2022President & Chief Executive OfficerInformative Buy9.84K$589.05K
CSCIF
Insider Shares: 105.00K (8.65%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
May 20, 2022Informative Buy$9.84K50,000$0.20-40.30%―
Sep 25, 2021Informative Buy$9.45K15,000$0.63-73.50%―
Apr 13, 2021Informative Buy$10.70K10,000$1.07-64.30%―
Apr 10, 2021Informative Buy$11.00K10,000$1.10-68.10%―
Aug 13, 2020Informative BuyC$11.00K20,000C$0.55+39.90%―

You May Also Like

Klaus Paulini insider profile FAQ

What is the percentage of profitable transactions made by Klaus Paulini?
The percentage of profitable transactions made by Klaus Paulini is 20%.
What is the average return per transaction made by Klaus Paulini?
The average return per transaction made by Klaus Paulini is -41.20%.
What stocks does Klaus Paulini hold?
Klaus Paulini holds: CSCIF stocks.
What was Klaus Paulini’s latest transaction?
Klaus Paulini’s latest transaction was an Informative Buy of $9.84K.
What was Klaus Paulini's most profitable transaction?
Klaus Paulini’s most profitable transaction was an Informative Buy of CSCIF stock on August 13, 2020. The return on the trade was 39.90%.
What is Klaus Paulini's role in COSCIENS Biopharma?
Klaus Paulini's role in COSCIENS Biopharma is President & Chief Executive Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.